Baclofen as relapse prevention in the treatment of Gamma-hydroxybutyrate (GHB) dependence: an open label study. - Baclofen and GHB dependence

Mental Health Care and Addiction Services (GGZ Nederland)/National program Scoring Results0 sites100 target enrollmentTBD

Overview

Phase: N/A
Intervention: Not specified
Conditions: Not specified
Sponsor: Mental Health Care and Addiction Services (GGZ Nederland)/National program Scoring Results
Enrollment: 100
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

TBD

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Investigators

Sponsor

Mental Health Care and Addiction Services (GGZ Nederland)/National program Scoring Results

Eligibility Criteria

Inclusion Criteria

•GHB dependence is the primary diagnosis, according to the DSM\-IV criteria. Patients are between 18\-65 years old and should be able to read and speak Dutch sufficiently

Exclusion Criteria

•Patients with any current physical or psychiatric safety concerns are excluded. Exclusion criteria are:
•\- Presence of a somatic safety concerns. These include liver cirrhosis and impaired renal function (as indicated by aspartate aminotransferase (AST), alanine transaminase (ALT), or gamma\-glutamyl transferase (GGT) level \>3 times the upper limit of normal (ULN); bilirubin \> ULN; serum creatinine \> ULN) , unstable hypertension, diabetes mellitus, and seizure disorder, including well controlled cases, currently taking anticonvulsants, insulin, or oral hypoglycemic and pregnancy.
•\- History or presence of a current psychiatric disorder, including any mood disorder (bipolar disorder or major depressive disorder), any psychotic disorder (including schizophrenia), and/or suicidal ideations.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting

N/A

Baclofen as treatment for relapse in GHB abuse

NL-OMON24379ijmegen Institute for Scientist-Practitioners in Addiction (NISPA)/ Mental Health Care and Addiction Services (GGZ Nederland)/National program Scoring Results100

Completed

N/A

Baclofen for maintenance treatment of opioid dependence: A randomised double-blind placebo-controlled clinical trial

ISRCTN32121581Roozbeh Addiction Department (Iran)40

Completed

Phase 3

Efficacy and safety of Baclofen GRS for treatment of alcohol dependence, a 12 week studyHealth Condition 1: F102- Alcohol dependenceHealth Condition 2: null- diagnosis of alcohol dependence

CTRI/2011/11/002154Sun Pharma Advanced Research Company Ltd195

Active, Not Recruiting

N/A

A placebo controlled trial with Baclofen for the treatment of GERD patients with incomplete PPI responseGastroesophageal reflux disease

EUCTR2009-017351-96-BEZleuven

Active, Not Recruiting

Phase 1

Study investigating the effect of baclofen in patients with postprandial regurgitation or belchingRumination syndrome and supragastric belchingMedDRA version: 14.0Level: LLTClassification code 10039292Term: Rumination disorderSystem Organ Class: 10037175 - Psychiatric disordersMedDRA version: 14.0Level: LLTClassification code 10004222Term: BelchingSystem Organ Class: 10017947 - Gastrointestinal disordersTherapeutic area: Diseases [C] - Digestive System Diseases [C06]

EUCTR2011-002745-35-BEZLeuven20